Mixed results for Moderna mRNA flu vaccine trial / Photo: Maddie Meyer - GETTY IMAGES/AFP
-
UK government urges cricket chiefs to 'deliver on own rules' after Afghanistan boycott calls
-
Barca's Olmo absence 'better' for us: Athletic coach Valverde
-
Jean-Marie Le Pen, architect of French far-right surge, dies at 96
-
Spurs boss Postecoglou not in favour of VAR stadium announcements
-
Meta abruptly ends US fact-checks ahead of Trump term
-
Quake in China's Tibet kills 126 with tremors felt in Nepal, India
-
Trump Jr in Greenland on 'tourist' day trip as father eyes territory
-
Postecoglou wants trophy for Son as Spurs extend contract
-
Loeb limps home as teenager wins Dakar stage
-
US trade deficit widens in November on imports jump
-
Macron irks allies, left with Africa 'forgot to say thank you' jibe
-
Key dates in the rise of the French far right
-
Meta announces ending fact-checking program in the US
-
Liverpool's Slot says contract issues not affecting Alexander-Arnold's form
-
Ghana's John Mahama sworn in after presidential comeback
-
Hundreds of young workers sue McDonald's UK alleging harassment
-
Jabeur beats Collins to step up comeback ahead of Melbourne
-
Eurozone inflation rises, likely forcing slower ECB rate cuts
-
France remembers Charlie Hebdo attacks 10 years on
-
Microsoft announces $3 bn AI investment in India
-
French far-right figurehead Jean-Marie Le Pen dies at 96
-
South Korea investigators get new warrant to arrest President Yoon
-
French far-right figurehead Jean-Marie Le Pen dies
-
South Sudan says will resume oil production from Jan 8
-
Pope names Sister Brambilla to head major Vatican office
-
Stock markets mostly rise on US optimism
-
Olmo's Barcelona registration battle puts Laporta under pressure
-
Taste of 2034 World Cup as Saudi Asian Cup stadiums named
-
Eurozone inflation picks up in December
-
France flanker Ollivon out for season, to miss Six Nations
-
S. Korea investigators get new warrant to arrest President Yoon
-
Tottenham trigger Son contract extension
-
China's most successful team kicked out of professional football
-
Eyeing green legacy, Biden declares new national monuments
-
South Korea rival parties form plane crash task force
-
Georgians hold anti-government protest on Orthodox Christmas
-
Japan actor fired from beer ad after drunken escapade
-
Nvidia ramps up AI tech for games, robots and autos
-
Blinken says US-Japan ties solid despite rift over steel deal
-
Quake in China's Tibet kills 95 with tremors felt in Nepal, India
-
Taiwan says Chinese-owned ship suspected of damaging sea cable goes dark
-
North Korea's Kim says new hypersonic missile will deter 'rivals'
-
Sinner turns focus to Australian Open defence after 'amazing' year
-
Ostapenko begins Adelaide title defence with comeback win
-
Asian markets mostly up after tech-fuelled Wall St rally
-
Pace of German emissions cuts slows in 2024: study
-
McDonald's rolls back some of its diversity practices
-
Giannis triple-double propels Bucks over Raptors
-
S. Korea rival parties form plane crash task force despite political turmoil
-
Quake in China's Tibet kills 53 with tremors felt in Nepal, India
NYSE - LSE
| RIO | 0.27% | 58.54 | $ | |
| BTI | -0.18% | 36.905 | $ | |
| CMSC | -0.36% | 23.405 | $ | |
| SCS | -1.19% | 11.305 | $ | |
| JRI | -1.43% | 12.275 | $ | |
| CMSD | -0.59% | 23.59 | $ | |
| BCE | 0.06% | 23.955 | $ | |
| NGG | 0.39% | 59.1 | $ | |
| BP | 1.6% | 31.525 | $ | |
| BCC | -1.13% | 118.88 | $ | |
| RYCEF | 1.53% | 7.2 | $ | |
| RBGPF | -4.54% | 59.31 | $ | |
| GSK | 0.93% | 34.28 | $ | |
| RELX | 0.89% | 46.06 | $ | |
| VOD | -0.41% | 8.435 | $ | |
| AZN | 0.19% | 66.964 | $ |
Mixed results for Moderna mRNA flu vaccine trial
US biotech company Moderna said Thursday it had mixed results from a large-scale trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine.
Moderna's experimental mRNA-1010 flu shot is "quadrivalent," meaning it targets four strains of flu: A/H1N1, A/H3N2, B/Yamagata and B/Victoria -- selected based on recommendations by the World Health Organization (WHO).
The Massachusetts-based company said that its flu shot generated an immune response against influenza A strains that was equal or superior to that of already licensed vaccines.
However, it fell short of the already approved vaccines against strains of the less-common influenza B, Moderna said in a statement.
"Today's results represent an important step forward in the development of mRNA-based influenza vaccines," Moderna president Stephen Hoge said.
"We have already updated the vaccine that we believe could improve immune responses against influenza B and will seek to quickly confirm those improvements in an upcoming clinical study."
The Phase 3 trial of the mRNA shot involved 6,102 adults in Argentina, Australia, Colombia, Panama, and the Philippines during the Southern Hemisphere influenza season.
Participants received a single dose of mRNA-1010 or a single dose of a licensed influenza vaccine.
Moderna said 70 percent of the mRNA-1010 recipients reported adverse reactions such as headaches, swelling and fatigue compared to 48 percent in the other group.
Virus strains have to be selected six to nine months before the vaccines are intended to be used, and their efficacy is approximately 40 to 60 percent.
Moderna is simultaneously conducting an efficacy trial of its vaccine.
Moderna and other vaccine manufacturers, including Sanofi, hope that mRNA technology -- which provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells -- can accelerate immunization development and production, and heighten efficacy.
There are some three to five million severe influenza cases annually worldwide and between 290,000 and 650,000 deaths, the WHO says.
Moderna's stock price was down more than six percent in after-hours trading in New York.
L.Durand--AMWN
